The elephant in the room
Ne umquam pars pro toto (Plinius). Can anyone remember a bit of Latin? This quotation was used in a slide presentation given a few weeks ago by Louis Denis, urologist and prostate cancer patient, at [more]
Number 78
Ne umquam pars pro toto (Plinius). Can anyone remember a bit of Latin? This quotation was used in a slide presentation given a few weeks ago by Louis Denis, urologist and prostate cancer patient, at the congress of the European As... [ more ]
Pain! The denial needs to end
Uncontrolled pain can blight the lives of cancer patients and survivors. But all too often, health professionals don’t ask, and patients don’t tell. Simon Crompton looks at why this is still the case, and what [more]
Ending substandard treatment in lung cancer
Lung cancer kills more people in Europe than any other type of cancer, yet efforts to monitor and improve standards of treatment and care have lagged behind those of less fatal cancers, such as breast [more]
Communication – the core skill that can make or break multiprofessional care
Complex healthcare cannot succeed without effective communication between everyone involved in the patient’s care, with each understanding and respecting the contribution of others. Peter McIntyre looks at where things can go wrong, and how to [more]
Ivana Božović-Spasojević: A Bordet for Belgrade
A chance to work at the heart of the trailblazing MINDACT trial gave Ivana Božović-Spasojević a memorable lesson in the value of international academic trials, and the logistics of how to run them. She spoke [more]
Complementary and integrative medicine for cancer patients – A purely ideological debate?
With studies showing that around half of all cancer patients use therapies that are not part of mainstream medicine, Cancer World Editor Alberto Costa explores some aspects of the discussion on what complementary and integrative [more]
Non-invasive metabolic imaging of brain tumours in the era of precision medicine
Sriram Venneti and colleagues examine non-invasive metabolic imaging strategies that can be used to interrogate some of the genomic alterations in brain tumours, with the ultimate goal of informing patient management. This is an abridged [more]
... [ more ]
Male breast cancer is not congruent with the female disease
Male breast cancer is almost always oestrogen receptor positive, and is traditionally treated in line with guidelines for treating hormone-sensitive breast cancers in postmenopausal women. Ian Fentiman questions the rationale for this approach, pointing to [more]
What can ’omics add to personalised risk assessment?
For a disease that has led the field of molecular biology, it is surprising perhaps that so few biomarkers have been identified that can predict a person’s risk of developing cancer. Researchers are now looking [more]
Reality check in Mumbai – Experts debate the evidence on leaving cancer care to the market
How far can private and philanthropic providers meet the rapidly rising need for cancer detection, treatment and care in low- and middle-income countries? Sandhya Srinivasan reports on a high-profile debate involving economists, policy makers, clinicians [more]